Urology FDA approvals of 2016 February 13, 2017By Urology Times StaffUrology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more. New Products: FDA approves combination regimen to treat advanced RCC July 20, 2016By Ben SchwartzOther products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more. RCC: Two approvals expand options for TKI-refractory patients June 29, 2016By Lisette HiltonFDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert. Uro Pipeline: IDE approval granted for implantable neurostimulator November 01, 2015By Benjamin P. SaylorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up. Product Preview: Agreement reached for phase III clinical trial of bladder Ca agent September 01, 2015By Benjamin P. SaylorIn this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis. FDA approves Lenvima for a type of thyroid cancer February 15, 2015By Erin BastickFDA has approved lenvatinib (Lenvima, Eisai) for the treatment of progressive, differentiated thyroid cancer.